X0305 4 2012-06-07 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001225509 SHEMA SUZANNE M C/O ONYX PHARMACEUTICALS, INC. 249 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP, General Counsel & Sec Common Stock 2012-06-07 4 M 0 30000 32.07 A 83639 D Common Stock 2012-06-07 4 M 0 10000 30.28 A 93639 D Common Stock 2012-06-07 4 S 0 3000 44.57 D 90639 D Common Stock 2012-06-07 4 S 0 3000 44.60 D 87639 D Common Stock 2012-06-07 4 S 0 4000 44.5834 D 83639 D Common Stock 2012-06-07 4 S 0 10000 44.6146 D 73639 D Common Stock 2012-06-07 4 S 0 10000 44.475 D 63639 D Common Stock 2012-06-07 4 S 0 10000 44.4351 D 53639 D Stock Option (Right to Buy) 32.07 2012-06-07 4 M 0 30000 0.00 D 2019-08-31 Common Stock 30000 47000 D Stock Option (Right to Buy) 30.28 2012-06-07 4 M 0 10000 0.00 D 2020-03-31 Common Stock 10000 21500 D Shares sold pursuant to a 10b5-1 plan. The shares were sold between $44.542 and $44.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold between $44.57 and $44.6652. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold between $44.32 and $44.5901. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold between $44.30 and $44.56. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Twenty-Five percent of the shares subject to the option become exercisable one year from the date of grant. The remaining shares become exercisable in equal monthly installments over the following 36 months for a total vesting schedule of 48 months. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months. /s/ Warren DeSouza, Attorney-in-fact 2012-06-08